Terumo operates worldwide, in 160 countries – 100 of these are covered by the agreement with BSD Medical. The agreement is not merely for distribution, it involves a collaborative relationship. Terumo evidently will be promoting and doing other marketing activities. Terrumo has about $5 billion in sales now, and they are energetically pursuing the rapidly-growing Interventional Oncology markets. And, the MTX-180 has been stated, by leading IO doctors, as providing far better ablation than the present market leader, RFA (radiofrequency ablation). BSD Medical mentions $2.3 billion as the market addressed by the MTX-180, and I have seen that number elsewhere (see Post 148).
BSD M.’s news release about the Terumo agreement says: Exclusive agreement for distribution in 100 countries; potential market size in excess of $1 billion in annual sales. Assuming BSD M. gets half of that income, that would translate (simple math) into a guesstimate of $50/sh increase in BSDM – from only that one product line! – and from only part of the world market.
http://www.terumo.com/about/pressrelease/2013/20130409.html
TOKYO—April 9, 2013 — Terumo Corporation announced today that its Terumo Europe NV subsidiary has signed an exclusive, long-term distribution agreement with BSD Medical Corporation for its MicroThermX® Microwave Ablation System (MicroThermX®). Under the terms of the distribution agreement, Terumo Europe NV will have the exclusive rights to market MicroThermX® in countries in Europe, Western Asia, and Northern Africa.
Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself in the last several years as a pioneer in the field of interventional oncology in Europe, marketing bland beads and drug eluting beads. Embolization, Trans Arterial Chemo Embolization (TACE) and ablation are "hand-in-hand" clinical cathlab-based procedures for the treatment of cancerous tumors and, when used together, provide a less invasive course of treatment to patients. This agreement therefore creates an ideal product synergy with BSD’s MicroThermX® product line and enables Terumo Europe NV to offer interventional radiologists and oncologists a complete and compelling therapy solution for the treatment of cancerous tumors.
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line innovative, high-end disposables - SynchroWave antennas.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world ’s leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic and laparoscopic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use |
